Urogen Pharma (URGN)
(Real Time Quote from BATS)
$17.73 USD
-0.41 (-2.26%)
Updated Oct 22, 2025 03:52 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
URGN 17.73 -0.41(-2.26%)
Will URGN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for URGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for URGN
MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last?
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
URGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss
Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?
Other News for URGN
Directional Movement Crossover Bullish appears for URGN after 0.81% move
Crossed Above 20 Day Moving Average appears for URGN after 6.17% move
Is URGN about to break its pattern? NR7 shows up after advancing 0.12%
URGN forms 20 Day Moving Average Resistance on October 16
20 Day Moving Average Resistance appears for URGN after 3.84% move